Company history

In 1936 three sake makers — Takara Shuzo, Godo Shusei and Nihon Shurui — jointly funded a small research house in Hatagaya, in Tokyo’s Shibuya ward: the Kyowa Chemical Research Institute, an offshoot of the brewers’ cartel Kyowa-kai. Its purpose was fermentation. Kato Benzaburo, dispatched from Takara Shuzo, led the work and developed a proprietary way to ferment molasses into butanol and convert it into aviation fuel — turning a by-product of the drinks trade toward the war.

The military pull drove a fast build-out — new plants at Fuji and Hofu in 1943, a wartime chemicals company (Toa Kagaku Kogyo) assembled around a requisitioned rayon works — but the molasses that fed the process came from the southern front, and as those shipping lanes were cut the plants never reached mass production. Japan lost the war before the fuel arrived. What the venture held, when the fighting stopped, was not a product but a capability: a deep command of industrial fermentation, and the hard-won habit of redirecting it once its purpose vanished. That habit would define the company for the next ninety years.

Under the postwar enterprise-reconstruction law, the old company was dissolved and Kyowa Hakko Kogyo was established in July 1949, after roughly 800 jobs were cut. Two years later a 1951 technology tie-up with America’s Merck put the company into domestic production of the tuberculosis drug streptomycin — the pivot that carried its fermentation base out of wartime munitions and into peacetime medicine. It backed the move with a $1.1M (¥400m) investment in the Hofu plant, larger than its own $750,000 (¥270m) of capital, staking its future on being the country’s leading fermentation drugmaker.

From the same technical root the company then fanned out. It expanded into spirits by buying up distillers from 1953; in 1956 it invented a fermentation route to MSG and went head-on with Ajinomoto; in 1959 it launched the anticancer drug Mitomycin, derived from a soil microbe isolated in Shibuya. By 1967 it had settled into a four-division structure — drugs, spirits, chemicals and food — an unusually broad spread for the era, all resting on one fermentation platform.

The breadth was also the constraint. In 1981 Kyowa Medix took the company into diagnostics and, with it, the long-horizon antibody research that would later underpin its biologics; in 1983 the founder, Kato Benzaburo, died, and leadership passed to salaried presidents whose job was to referee four very different businesses; in 1991 Coniel extended the drug line into cardiovascular care. But running four businesses of sharply different profitability under a drugmaker’s cost base and management could no longer absorb the gaps between them — the seed of the divestitures to come.

The dismantling came fast. In 2001 Janssen Kyowa was sold to Johnson & Johnson; in 2002 the spirits business went to Asahi Breweries — a reversal of the founding creed of diversification, since spirits had grown from the very fermentation the company was built on. Chemicals was spun off as Kyowa Hakko Chemical in 2004 and food as Kyowa Hakko Foods in 2005. The half-century-old four-division structure was taken apart within a few years, an irreversible signal that the company would now be about drugs alone.

Then it lost its independence. In October 2007 Kirin Holdings declared a tender offer that closed that December with a 28.49% voting stake, and by April 2008 a share exchange had lifted its holding to 50.10%, citing the complementarity of the two firms’ fermentation science and the scale it would bring to drug R&D. President Yuzuru Matsuda framed it as consensual — with 70–80% internal support — rather than hostile. Yet giving up independence installed a parent whose intentions would shape strategy, capital spending and personnel thereafter; the diversified fermentation company became the pharmaceutical arm of a large group.

In October 2008 it absorbed Kirin Pharma and renamed itself Kyowa Hakko Kirin, for a consideration of $4.6B (¥478bn) that put $1.9B (¥192bn) of goodwill on the balance sheet — a bet that R&D and the drug pipeline would earn it back, so that the company’s future rode on a handful of antibody medicines. It then shed the last of its non-pharma businesses and, under Kirin’s balance sheet, pushed abroad: buying the UK’s ProStrakan for $493.9M (¥39bn) in 2011 for a European sales network and a rare-disease pipeline, and Archimedes Pharma in 2014. Fermentation to antibody drugs, Japan to Britain — a double shift of gravity that set its new competitive ground.

In 2019 the company renamed itself Kyowa Kirin and, in the same year, sold a 95% stake in its Kyowa Hakko Bio subsidiary to its parent, Kirin Holdings, for roughly $1.2B (¥128bn), booking a $443.1M (¥48bn) gain — handing away a stable, high-earning business to shrink its own base to drugs alone. With the parent holding 50.10% of the shares, the board’s room to say no was structurally narrow; the logic of capital set the terms. The parent-subsidiary listing itself had come to draw the outline of the company.

What remained was a single strategy: an antibody-centred global specialty pharma aimed at rare disease, immunology and oncology, deliberately sidestepping head-on fights with the mega-caps to work fields others had left open. President Masashi Miyamoto framed it around helping patients that existing drugs could not. Crysvita, for a rare bone disease, and Poteligeo, in oncology, became its first global products; in 2024 it bought the UK’s Orchard Therapeutics and its hematopoietic-stem-cell gene therapy Libmeldy, extending the British-biotech line begun with ProStrakan. Revenue reached $3.1B (¥442bn) in 2023, and the focus was paying off.

From 2024 the same select-and-concentrate logic began operating one level down, inside the drug business itself: Europe’s established-products line was folded into a joint venture with Germany’s Grünenthal, the China subsidiary was sold and APAC distribution handed to DKSH and WinHealth, and a special early-retirement round ran in Japan in 2025. Keep North America and EMEA rare-disease drugs; drop the slow-growers and the distant markets. What once shrank four divisions to one now works at the scale of a single country and therapeutic area. Left unresolved is the governance question the parent-subsidiary listing keeps posing — minority-shareholder interest against parent strategy — and it still shadows the valuation.